文献速递特殊人群用药药物相互作用治疗药物监测与药物基因组学

多替拉韦群体药代动力学建模:叙述性综述

Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review.
PubMed 文献 · Clin Pharmacokinet · 2026-06-30

几乎所有模型对表观清除率和/或表观分布容积采用异速增长缩放,校正体型后各人群清除率与分布容积相似;成人吸收速率常数较高且跨人群变异性大。研究模拟与预设靶值提示推荐剂量可达有效暴露,但孕妇和新生儿数据有限。

要点

  • 校正体型后多替拉韦清除率与分布容积在成人与儿童等人群间相似。
  • 成人吸收速率常数较高且跨人群变异性大,合并用药和背景抗逆转录病毒药是常见协变量。
  • 孕妇和新生儿数据有限,推荐剂量经模拟显示可达预设靶值。

核心结论

  • 现有群体药代动力学模型显示,校正体型后多替拉韦清除率与分布容积在各人群间相似,推荐剂量经模拟可达预设靶值。
  • 孕妇、早产儿、儿童、肥胖和老年人等浓度易变人群的数据仍有限,需进一步表征。

研究设计与样本

  • 共纳入23项研究:成人15项、儿童4项、妊娠2项(母亲及新生儿)、足月新生儿2项。

主要发现

  • 几乎所有模型对表观清除率和/或表观分布容积参数采用异速增长缩放,体重尤其重要。
  • 校正体型差异后,表观清除率和表观分布容积在各人群间相似。
  • 成人吸收速率常数较高,且跨人群变异性大。
  • 成人和儿童中常见协变量包括合并用药和背景抗逆转录病毒治疗。
  • 孕妇和新生儿的数据及 tested 协变量有限。

关键数值与推荐

  • 研究模拟和预设靶值提示推荐的多种替拉韦剂量可达有效暴露。

临床怎么用

  • 临床可参考群体药代动力学模型中的协变量(体重、合并用药、背景抗逆转录病毒药)评估多替拉韦暴露。
  • 对孕妇、新生儿、儿童、肥胖和老年人等数据有限人群,应关注浓度变化风险并加强监测。

局限性

  • 孕妇和新生儿的数据及 tested 协变量有限。
  • 早产儿、儿童、妊娠、肥胖和老年人等浓度易变人群仍需进一步表征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dolutegravir-based regimens are part of the preferred regimens in all populations living with HIV, but dolutegravir's pharmacokinetics can vary greatly with factors such as drug-drug interactions (DDIs) and age. For example, DDIs between dolutegravir and rifamycins in countries with a high burden of HIV/tuberculosis co-infection present a major challenge. Attaining therapeutic concentrations is crucial for virologic success and to prevent resistance. Understanding dolutegravir pharmacokinetics and its sources of variability is essential to ensure adequate exposure in all individuals. Population pharmacokinetic (PopPK) modeling is a powerful tool for characterizing medication disposition. In this review, we aim to synthesize existing dolutegravir PopPK models, highlighting key pharmacokinetic parameters and covariate effects. A literature search was done on Medline and Embase databases from inception to November 18th, 2025. This review included 23 studies: 15 in adults, 4 in pediatrics, 2 in pregnancy (mothers and their newborn), and 2 in term neonates. Almost all models included allometric scaling, with body weight especially, on apparent clearance (CL/F) and/or apparent volume of distribution (Vd/F) parameters. When considering differences in body size, CL/F and Vd/F were similar across populations. The absorption rate constant (ka) was higher in adults and presented high variability across populations. Other common covariates in adults and pediatrics were co-medications and background antiretrovirals. Data and tested covariates were limited in pregnant women and neonates. Study simulations and predefined target values indicated adequate recommended dolutegravir doses. Further characterization of dolutegravir PopPK in populations at risk of altered concentrations (e.g., preterm neonates, pediatrics, pregnancy, obesity, and older adults) is crucial to better understand dolutegravir pharmacokinetics in these populations as data are still limited.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Pilote É, Sheehan NL, Marsot A, et al. Population Pharmacokinetic Modelling of Dolutegravir: A Narrative Review. Clin Pharmacokinet. 2026. PMID: 42377866. doi:10.1007/s40262-026-01653-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。